ALXO

ALX Oncology (ALXO)

ALX Oncology Holdings Inc

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:ALXO

1 2 3 4 5 6 7 8 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2024/05/16	05 : 30	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:ALXO	ALX Oncology Holdings Inc
2024/05/14	05 : 06	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:ALXO	ALX Oncology Holdings Inc
2024/05/10	05 : 10	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:ALXO	ALX Oncology Holdings Inc
2024/05/10	05 : 00	GlobeNewswire Inc.	ALX Oncology Reports First Quarter 2024 Financial Results and Provides Corporate Update	NASDAQ:ALXO	ALX Oncology Holdings Inc
2024/05/09	06 : 31	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:ALXO	ALX Oncology Holdings Inc
2024/05/07	22 : 00	GlobeNewswire Inc.	ALX Oncology Appoints Allison Dillon as Chief Business Officer	NASDAQ:ALXO	ALX Oncology Holdings Inc
2024/05/07	05 : 02	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:ALXO	ALX Oncology Holdings Inc
2024/04/30	22 : 00	GlobeNewswire Inc.	ALX Oncology Announces Initiation of Phase 2 Investigator-Sponsored Trial of Neoadjuvant Radiation and Evorpacept in Combination with Pembrolizumab in Patients with Untreated HPV-Mediated Oropharyngeal Cancer	NASDAQ:ALXO	ALX Oncology Holdings Inc
2024/04/24	23 : 00	GlobeNewswire Inc.	ALX Oncology Announces Two Evorpacept Abstracts Accepted for Poster Presentation at 2024 ASCO Annual Meeting	NASDAQ:ALXO	ALX Oncology Holdings Inc
2024/04/10	06 : 30	GlobeNewswire Inc.	ALX Oncology Reports Encouraging Clinical Data of Evorpacept in Combination with Standard-of-Care in an Ongoing Phase 1/2 Clinical Trial in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (“R/R B-NHL”)	NASDAQ:ALXO	ALX Oncology Holdings Inc
2024/03/08	06 : 05	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:ALXO	ALX Oncology Holdings Inc
2024/03/08	06 : 03	GlobeNewswire Inc.	ALX Oncology Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update	NASDAQ:ALXO	ALX Oncology Holdings Inc
2024/03/06	06 : 30	GlobeNewswire Inc.	ALX Oncology Announces Two Evorpacept Clinical Abstracts Accepted for Presentation at the AACR Annual Meeting	NASDAQ:ALXO	ALX Oncology Holdings Inc
2024/02/17	08 : 24	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:ALXO	ALX Oncology Holdings Inc
2024/02/17	08 : 17	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:ALXO	ALX Oncology Holdings Inc
2024/02/17	08 : 09	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:ALXO	ALX Oncology Holdings Inc
2024/01/06	06 : 03	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:ALXO	ALX Oncology Holdings Inc
2024/01/04	06 : 28	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:ALXO	ALX Oncology Holdings Inc
2024/01/04	06 : 25	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:ALXO	ALX Oncology Holdings Inc
2024/01/04	06 : 17	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:ALXO	ALX Oncology Holdings Inc
2024/01/03	22 : 00	GlobeNewswire Inc.	ALX Oncology to Present at the 42nd Annual J.P. Morgan Healthcare Conference	NASDAQ:ALXO	ALX Oncology Holdings Inc
2023/12/27	06 : 01	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:ALXO	ALX Oncology Holdings Inc
2023/11/14	06 : 05	GlobeNewswire Inc.	ALX Oncology Reports Third Quarter 2023 Financial Results and Provides Corporate Update	NASDAQ:ALXO	ALX Oncology Holdings Inc
2023/11/14	06 : 03	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:ALXO	ALX Oncology Holdings Inc
2023/11/02	05 : 05	GlobeNewswire Inc.	ALX Oncology Announces November Investor Conference Participation	NASDAQ:ALXO	ALX Oncology Holdings Inc
2023/10/11	05 : 05	GlobeNewswire Inc.	ALX Oncology Announces Closing of Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares	NASDAQ:ALXO	ALX Oncology Holdings Inc
2023/10/06	19 : 06	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:ALXO	ALX Oncology Holdings Inc
2023/10/06	19 : 05	Edgar (US Regulatory)	Form 424B5 - Prospectus [Rule 424(b)(5)]	NASDAQ:ALXO	ALX Oncology Holdings Inc
2023/10/05	21 : 00	GlobeNewswire Inc.	ALX Oncology Announces Pricing of Public Offering	NASDAQ:ALXO	ALX Oncology Holdings Inc
2023/10/05	06 : 21	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:ALXO	ALX Oncology Holdings Inc